Horizon Pharma Public Limited Company, a biopharmaceutical company, focuses on researching, developing, and commercializing medicines that address unmet treatment needs for rare and rheumatic diseases in the United States and internationally. The company's orphan and rheumatology marketed medicines include KRYSTEXXA, a medicine for the treatment of uncontrolled gout; RAVICTI for use as a nitrogen-binding agent for chronic management of adult and pediatric patients; PROCYSBI for nephropathic cystinosis, a rare and life-threatening metabolic disorder; ACTIMMUNE for chronic granulomatous disease; RAYOS for the treatment of multiple conditions, rheumatoid arthritis; BUPHENYL tablets for oral administration and BUPHENYL powder for oral, nasogastric, or gastrostomy tube administration; and QUINSAIR, a formulation of the antibiotic drug levofloxacin for the management of chronic pulmonary infections due to Pseudomonas aeruginosa in adult patients with cystic fibrosis. Its primary care marketed medicines comprise PENNSAID 2% that is indicated for the treatment of pain of osteoarthritis of the knees; DUEXIS for the relief of signs and symptoms of RA and OA, and to decrease the risk of developing upper-GI ulcers; VIMOVO for the relief of signs and symptoms of OA, RA, and AS and to decrease the risk of developing gastric ulcers in patients at risk of developing NSAID-associated gastric ulcers; and MIGERGOT, a therapy to abort or prevent vascular headaches, such as migraines and migraine variants. Horizon Pharma Public Limited Company has collaboration agreements with Alliance for Lupus Research to evaluate RAYOS/LODOTRA on the fatigue experienced by systemic lupus erythematosus patients; Syneos Health, Inc. in connection with its Phase III confirmatory trial to evaluate teprotumumab for the treatment of thyroid eye disease; and HemoShear Therapeutics, LLC to discover and develop therapeutics for gout. The company was founded in 2005 and is headquartered in Dublin, Ireland.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryPharmaceuticals
SectorMedical
Phone011-353-1772-2100
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$1.21 billion
Profitability
Miscellaneous
Employees1,000
Next Earnings Date5/8/2019 (Estimated)
OptionableOptionable
Horizon Pharma (NASDAQ:HZNP) Frequently Asked Questions
What is Horizon Pharma's stock symbol?
Horizon Pharma trades on the NASDAQ under the ticker symbol "HZNP."
How will Horizon Pharma's stock buyback program work?
Horizon Pharma declared that its Board of Directors has authorized a stock buyback program on Sunday, June 4th 2017, which authorizes the company to buyback 1,000% of shares, according to EventVestor. This buyback authorization authorizes the company to reacquire shares of its stock through open market purchases. Shares buyback programs are usually an indication that the company's board of directors believes its stock is undervalued.
How were Horizon Pharma's earnings last quarter?
Horizon Pharma PLC (NASDAQ:HZNP) released its earnings results on Wednesday, February, 27th. The biopharmaceutical company reported $0.67 earnings per share for the quarter, beating the Zacks' consensus estimate of $0.54 by $0.13. The biopharmaceutical company earned $355.50 million during the quarter, compared to analyst estimates of $334.22 million. Horizon Pharma had a negative net margin of 6.34% and a positive return on equity of 34.09%. The business's revenue for the quarter was up 29.6% on a year-over-year basis. During the same period in the prior year, the company posted $0.29 EPS. View Horizon Pharma's Earnings History.
When is Horizon Pharma's next earnings date?
What guidance has Horizon Pharma issued on next quarter's earnings?
Horizon Pharma updated its FY 2019 earnings guidance on Wednesday, February, 27th. The company provided EPS guidance of for the period. The company issued revenue guidance of $1.23-1.25 billion, compared to the consensus revenue estimate of $1.24 billion.
What price target have analysts set for HZNP?
11 analysts have issued 12 month target prices for Horizon Pharma's shares. Their predictions range from $18.00 to $38.00. On average, they anticipate Horizon Pharma's share price to reach $29.00 in the next year. This suggests a possible upside of 2.8% from the stock's current price. View Analyst Price Targets for Horizon Pharma.
What is the consensus analysts' recommendation for Horizon Pharma?
11 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Horizon Pharma in the last year. There are currently 3 hold ratings and 8 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Horizon Pharma.
What are Wall Street analysts saying about Horizon Pharma stock?
Here are some recent quotes from research analysts about Horizon Pharma stock:
- 1. According to Zacks Investment Research, "Horizon faces intense competition from pharmaceutical and biotechnology companies, and universities and other research institutions.Horizon is working on label expansion of drug like Ravicti. Failing to gain regulatory approval for label expansions would hamper drugs’ commercial potential. The company is exploring a broader clinical profile of Krystexxa including adapting its MIRROR immunomodulation study based on promising recent data to support the potential for registration.The company’s clinical programs continue to advance, with the recent presentation of new teprotumumab phase II data that underscore the durable efficacy observed in thyroid eye disease. Shares of the company have outperformed the industry in the past year. Estimates have remained stable ahead of the Q4 results. The company has positive earnings surprise in the last few quarters." (2/8/2019)
- 2. Mizuho analysts commented, "We believe the event could have +10% upside/-30% downside to the stock (and is risky), because expectations for a positive read-out are already quite high. HZNP already advanced +17% YTD into the event. The company has discussed with us the opportunity as capturing 50% share in the 15,000-20,000 moderate/ severe active TED patients, with a $100K net price for treatment to achieve its estimates of >$750M. In contrast, we currently assume a ~15% share, and net price of $210K/treatment in 2020, with net price increases of 5% thereafter (based on prior mgmt. commentary on Orphan pricing). We will update our estimates after the data, which we believe will determine the commercial attractiveness of this compound. We reiterate our Neutral rating, and continue to view 2019 consensus earnings estimates as too high." (2/7/2019)
- 3. Cantor Fitzgerald analysts commented, ". We are raising our 12-month PT for HZNP shares to $23 from $21. The increase in our PT is driven by multiple expansion. We think this is deserved because continued solid execution from the management team underscores our belief that the peak sales potential of HZNP’s orphan/rare disease as well as rheumatology businesses are underappreciated." (10/18/2018)
- 4. Cowen Inc analysts commented, "Sarepta (SRPT) reported 2Q18 sales/earnings and provided a business update on 8/8. Exondys51 sales of $74M topped our expectations (see below) by 5%, and accelerated sequentially in 2Q18, after a slight dip in 1Q18. However, SRPT kept its FY18 guidance unchanged. OPEX is increasing faster than expectations, with FY18E non-GAAP OPEX potentially >2X 2016 levels of $198M. With sales growth starting to slow to high single digits Q/Q, focus is increasingly turning to the early/mid-stage pipeline to deliver commercial products in the near term. We continue to believe that gene therapy projects will take a minimum of 3-5 years to get to market and the exon- skipping agents (53 & 45) on-market by 2020. We stay neutral on the name." (8/9/2018)
Has Horizon Pharma been receiving favorable news coverage?
Press coverage about HZNP stock has been trending somewhat positive this week, InfoTrie reports. The research firm rates the sentiment of media coverage by analyzing more than six thousand blog and news sources. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Horizon Pharma earned a media sentiment score of 1.3 on InfoTrie's scale. They also assigned news stories about the biopharmaceutical company a news buzz of 10.0 out of 10, meaning that recent media coverage is extremely likely to have an effect on the stock's share price in the next several days.
Who are some of Horizon Pharma's key competitors?
Some companies that are related to Horizon Pharma include Teva Pharmaceutical Industries (TEVA), BioMarin Pharmaceutical (BMRN), UCB (UCBJF), Ono Pharmaceutical (OPHLF), Mylan (MYL), Merck KGaA (MKGAF), GRIFOLS S A/S (GRFS), Ionis Pharmaceuticals (IONS), Genmab A/S (GNMSF), Alnylam Pharmaceuticals (ALNY), Sarepta Therapeutics (SRPT), Bausch Health Companies (BHC), Beigene (BGNE), Jazz Pharmaceuticals (JAZZ) and SAGE Therapeutics (SAGE).
What other stocks do shareholders of Horizon Pharma own?
Who are Horizon Pharma's key executives?
Horizon Pharma's management team includes the folowing people:
- Mr. Timothy P. Walbert, Chairman, Pres & CEO (Age 52)
- Mr. Paul W. Hoelscher, Exec. VP & CFO (Age 54)
- Mr. Barry J. Moze, Exec. VP & Chief Admin. Officer (Age 65)
- Ms. Irina Konstantinovsky, Exec. VP & Chief HR Officer (Age 49)
- Mr. Miles W. McHugh, Chief Accounting Officer & Sr. VP (Age 54)
Who are Horizon Pharma's major shareholders?
Horizon Pharma's stock is owned by a variety of of institutional and retail investors. Top institutional shareholders include BlackRock Inc. (8.29%), Dimensional Fund Advisors LP (3.07%), venBio Select Advisor LLC (2.60%), D. E. Shaw & Co. Inc. (2.01%), Eagle Asset Management Inc. (1.61%) and Norges Bank (1.42%). Company insiders that own Horizon Pharma stock include Brian K Beeler, Geoffrey M Curtis, Michael G Grey and Timothy P Walbert. View Institutional Ownership Trends for Horizon Pharma.
Which major investors are selling Horizon Pharma stock?
HZNP stock was sold by a variety of institutional investors in the last quarter, including Bank of America Corp DE, Brandywine Global Investment Management LLC, Dimensional Fund Advisors LP, Segall Bryant & Hamill LLC, Barings LLC, Bank of Montreal Can, venBio Select Advisor LLC and Prudential Financial Inc.. Company insiders that have sold Horizon Pharma company stock in the last year include Brian K Beeler, Geoffrey M Curtis and Timothy P Walbert. View Insider Buying and Selling for Horizon Pharma.
Which major investors are buying Horizon Pharma stock?
HZNP stock was acquired by a variety of institutional investors in the last quarter, including Norges Bank, FMR LLC, D. E. Shaw & Co. Inc., Emerald Advisers LLC, Emerald Mutual Fund Advisers Trust, Jennison Associates LLC, Two Sigma Investments LP and Two Sigma Advisers LP. View Insider Buying and Selling for Horizon Pharma.
How do I buy shares of Horizon Pharma?
Shares of HZNP can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Horizon Pharma's stock price today?
One share of HZNP stock can currently be purchased for approximately $28.22.
How big of a company is Horizon Pharma?
Horizon Pharma has a market capitalization of $4.79 billion and generates $1.21 billion in revenue each year. The biopharmaceutical company earns $-74,190,000.00 in net income (profit) each year or $1.83 on an earnings per share basis. Horizon Pharma employs 1,000 workers across the globe.
What is Horizon Pharma's official website?
How can I contact Horizon Pharma?
Horizon Pharma's mailing address is 1 BURLINGTON ROAD CONNAUGHT HOUSE 1ST FLOOR, DUBLIN L2, D04 C5Y6. The biopharmaceutical company can be reached via phone at 011-353-1772-2100 or via email at [email protected]
MarketBeat Community Rating for Horizon Pharma (NASDAQ HZNP)
MarketBeat's community ratings are surveys of what our community members think about Horizon Pharma and other stocks. Vote "Outperform" if you believe HZNP will outperform the S&P 500 over the long term. Vote "Underperform" if you believe HZNP will underperform the S&P 500 over the long term. You may vote once every thirty days.
